

September 25, 2026

To

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C-1, G- Block,
Bandra - Kurla Complex, Bandra (East)
Mumbai – 400 051.

BSE Limited

Corporate Relationship Department
25, P.J. Towers,
Dalal Street,
Mumbai 400 001.

Symbol: RPGLIFE

Scrip Code: 532983

Dear Sir/Madam,

SUB: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended ("Listing Regulations")

REF: Scheme of Amalgamation of Actis Generics Private Limited with RPG Active Pharma Limited and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013.

This is to inform that we have received an intimation at 20.12 hrs (IST) on September 25, 2026 from our subsidiary company namely, RPG Active Pharma Limited ("RPGAP") that its Board of Directors at its meeting held today, has approved a Scheme of Amalgamation of Actis Generics Private Limited ("Actis Generics" or "Transferor Company"), (a wholly owned subsidiary of RPGAP) with RPGAP ("Transferee Company") and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ("Act") ("Scheme").

The Scheme is subject to receipt of necessary approvals from the jurisdictional bench of the National Company Law Tribunal, shareholders of RPG Active and Actis Generics, and such other persons and authorities, as may be required.

The details required pursuant to SEBI Master Circular No. HO/49/14/14(7)2025-CFD POD2/I/3762/2026 dated January 30, 2026, are given in Annexure I.

Yours Sincerely,

For RPG Life Sciences Limited

RAJESH
RAMESH
SHIRAMBEKAR

Digitally signed by RAJESH
RAMESH SHIRAMBEKAR
Date: 2026.09.26 01:13:11
+05'30'

Rajesh Shirambekar
Head – Legal & Company Secretary

Encl: as above.

Annexure I – Brief details of Amalgamation / Merger

a)	Name of the entity(ies) forming part of the amalgamation/ merger, details in brief such as size, turnover etc.	1.RPG Active Pharma Limited ("Transferee Company") Net worth – INR 34.75 Crore (As on March 31, 2026). As, RPGAP was incorporated on 24th December 2025, it did not have any revenue from operations in FY26. 2.Actis Generics Private Limited ("Transferor Company") Net worth – INR 34.60 Crore (As on March 31, 2026), Revenue from operations – INR 45.96 Crore (during financial year 2025-26).
b)	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arms' length"	Yes, both the companies involved in the transaction are related parties to each other. However, in terms of General Circular No. 30/2014 dated 17th July 2014 issued by Ministry of Corporate Affairs ("MCA Circular"), the transactions arising out of compromises, arrangements and amalgamations under the Companies Act, 2013 ("Act"), will not attract the requirements of Section 188 of the Act.
c)	Area of business of the entity(ies)	a) The Transferor Company is, <i>inter alia</i>, engaged in the business of manufacturing of pharmaceutical, medical chemicals and botanical products; and b) The Transferee Company is, <i>inter alia</i>, engaged in the business of manufacturing and marketing of active pharmaceutical ingredients.
d)	Rationale for amalgamation/ merger	1. The Transferor Company is a wholly owned subsidiary of the Transferee Company. It is proposed to amalgamate the Transferor Company with the Transferee Company to consolidate the assets and liabilities of the Transferor Company pursuant to amalgamation. The Scheme provides for the amalgamation of the Transferor Company with the Transferee Company and will result in the following benefits: a. streamlining of the corporate structure and consolidation of assets and liabilities of the Transferor Company with the Transferee Company leading to value consolidation; b. more efficient utilization of capital for enhanced development and growth of the consolidated business in one entity; c. easier implementation of corporate actions through simplified compliance structure; d. improve management oversight and bring in operational efficiencies; e. cost savings through legal entity rationalisation and consolidation of various functions, business processes, elimination of duplicate expenses, etc;

		f. reduction of administrative responsibilities, multiplicity of records and legal & regulatory compliances; g. stronger balance sheet and net worth of the Transferee Company entails scope for better facilitation terms with existing and potential lenders to meet capital needs for business purposes; h. the increased asset base of the Transferee Company would benefit all the stakeholders including the creditors of the Transferor Company and the Transferee Company, who would continue to be associated with the Transferee Company; and i. better business synergy in Active Pharmaceutical Ingredients and Intermediaries. j. Thus, the amalgamation is in the interest of the shareholders, creditors and all other stakeholders of the Transferor Company and the Transferee Company and is not prejudicial to or affecting the rights and interests of the concerned shareholders, creditors or the public at large.
e)	In case of cash consideration – amount or otherwise share exchange ratio	The Transferor Company is a wholly owned subsidiary of the Transferee Company and therefore, there shall be no issue of shares as consideration for the amalgamation of the Transferor Company with the Transferee Company. Upon the Scheme becoming effective, all shares of the Transferor Company held by the Transferee Company along with its nominees, shall stand cancelled without any further application, act, instrument or deed and be of no effect without any necessity of them being surrendered.
f)	Brief details of change in shareholding pattern (if any) of listed entity	Upon the Scheme becoming effective, there shall be no change in the shareholding pattern of the Company.